Teleflex earnings release, August 6, 2026

Teleflex Inc (TFX) · Form 8-K, Item 2.02 · Filed · SEC filing

Teleflex Reports

Second

Quarter Finan cial Results and Full Year 2026 Outlook

Completes Sale of OEM Business and Will Deploy Net Proceeds to Reduce Debt and Repurchase Common Stock

Announces $250 Million Accelerated Share Repurchase Program, Repurchased $250 Million of Common Stock in the Second Quarter

Wayne, PA --

Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026.

Second quarter 2026 continuing operations financial summary¹

• Revenue from continuing operations of $570.3 million, up 28.9% compared to the prior year period, and up 4.7% on a pro forma adjusted constant currency basis

1,2

• GAAP diluted EPS from continuing operations of $0.96, compared to $1.54 in the prior year period

• Adjusted diluted EPS from continuing operations of $1.76, compared to $1.73 in the prior year period

"We delivered a strong second quarter, led by excellent performance in our Vascular and Surgical businesses, while continuing to take decisive actions to strengthen the company for the future,” said Jason Weidman, Teleflex's President and Chief Executive Officer. “The completion of the OEM divestiture marks a pivotal step in our transformation, enabling greater focus on our core businesses, a stronger balance sheet, and increased financial flexibility to further reduce debt, return capital to shareholders, and invest in the opportunities that will drive long-term growth. We also made meaningful progress advancing our innovation pipeline, including important milestones for Freesolve and the Food and Drug Administration approval for EZPLAZ, reinforcing our commitment to bringing differentiated solutions to the market.”

Mr. Weidman continued, "Integration of the acquired Biotronik Vascular Intervention business is progressing, though taking longer than expected, and we updated our revenue outlook accordingly. Importantly, the delay is attributable to elongated integration timelines and not the underlying product portfolio, which remains competitively well positioned. We remain confident in the long-term strategic and financial prospects of this business as part of Teleflex, and have a number of mitigation actions underway to address the primary drivers of the delay. Our updated outlook also reflects the benefits of our disciplined capital allocation actions, including an increase to our adjusted EPS guidance."

Turning to his priorities as CEO, Weidman said: "I’m encouraged by the progress our team is making across the organization. Looking ahead, I am focused on completing a thorough assessment of the business and sharpening our strategic and operating plan to maximize shareholder value. My priorities are operational rigor, accelerating our innovation-driven¹ platforms, and disciplined capital deployment. We believe these efforts will position Teleflex to deliver a meaningfully stronger financial profile in 2027 and beyond."

2026 continuing operations guidance summary¹

• Reducing GAAP revenue growth guidance range to 13.40% to 14.40%

• Reducing GAAP EPS from continuing operations guidance range to $2.54 to $2.84

• Reducing pro forma adjusted constant currency revenue growth guidance range to 3.50% to 4.50%²

• Increasing Adjusted diluted EPS from continuing operations guidance range to $6.90 to $7.20

◦ Includes an assumption of approximately 19% adjusted operating margin for 2026 inclusive of transition services ("TS") associated with the close of the OEM Strategic Divestiture

◦ Reflects execution of capital allocation strategy including $250 million of share repurchase activity in the second quarter of 2026 and pay off of ~$700 million Term Loan A-2

◦ Excludes expected benefits from TS and manufacturing services ("MS") agreements that come into effect upon closing the Acute Care and Interventional Urology Strategic Divestiture

◦ Excludes the impact of the announced $250 million Accelerated Share Repurchase and other anticipated future repurchases under previously announced $1 billion share repurchase program primarily funded with proceeds from the Strategic Divestitures

◦ Adjusted diluted EPS from continuing operations excludes any impact of potential IEEPA tariff refunds

Financial statements

Income Statement

Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation

LowHigh
Forecasted GAAP diluted earnings per share from continuing operations2.542.84
Restructuring and optimization items, net of tax0.980.98
Acquisition, integration and divestiture related items, net of tax0.730.73
Other items, net of tax-0.42-0.42
ERP implementation, net of tax0.310.31
MDR, net of tax0.020.02
Intangible amortization expense, net of tax2.742.74
Forecasted adjusted diluted earnings per share from continuing operations, net of tax6.97.2

Income Statement

Three Months Ended — (Unaudited) (Dollars and shares in thousands, except per share)

Three Months Ended – June 30, 2026 – (Dollars and shares in thousands, except per share)Three Months Ended – June 29, 2025 – (Dollars and shares in thousands, except per share)Six Months Ended – June 30, 2026 – (Dollars and shares in thousands, except per share)Six Months Ended – June 29, 2025 – (Dollars and shares in thousands, except per share)
Net revenues570,332442,5251,118,594856,783
Cost of goods sold238,625176,695479,461335,522
Gross profit331,707265,830639,133521,261
Selling, general and administrative expenses213,515137,504439,527290,419
Research and development expenses45,12226,48889,50851,783
Restructuring charges, separation costs and impairment charges24610,70017,09112,122
Income from continuing operations before interest, taxes and loss on extinguishment of debt72,82491,13893,007166,937
Interest expense27,95321,70353,67140,240
Interest income-1,416-1,229-3,124-2,717
Loss on extinguishment of debt1,1501,150
Income from continuing operations before taxes45,13770,66441,310129,414
Taxes on income from continuing operations3,3752,4894,3868,906
Income from continuing operations41,76268,17536,924120,508
Operating income from discontinued operations60,25464,57757,611114,637
Taxes on operating income from discontinued operations2,32310,1722,99617,563
Income from discontinued operations57,93154,40554,61597,074
Net income99,693122,58091,539217,582
Basic:Income from continuing operations0.961.540.842.68
Basic:Income from discontinued operations1.331.231.242.15
Basic:Net income2.292.772.084.83
Diluted:Income from continuing operations0.961.540.842.67
Diluted:Income from discontinued operations1.321.231.242.15
Diluted:Net income2.282.772.084.82
Weighted average common shares outstandingBasic43,56244,26943,90845,017
Weighted average common shares outstandingDiluted43,66044,33244,01445,120

Balance Sheet

June 30, 2026 — (Unaudited) (in thousands)

June 30, 2026December 31, 2025
Current assetsCash and cash equivalents300,159378,564
Current assetsAccounts receivable, net364,609345,583
Current assetsInventories351,912404,395
Current assetsPrepaid expenses and other current assets148,222150,678
Current assetsPrepaid taxes36,45819,566
Current assetsCurrent assets of discontinued operations674,516639,552
Current assetsTotal current assets1,875,8761,938,338
Current assetsProperty, plant and equipment, net475,637498,281
Current assetsOperating lease assets77,15891,817
Current assetsGoodwill2,292,4352,305,050
Current assetsIntangible assets, net1,448,6691,524,150
Current assetsDeferred tax assets12,64212,593
Current assetsOther assets120,310112,984
Current assetsNon-current assets of discontinued operations484,051464,026
Current assetsTotal assets6,786,7786,947,239
Current liabilitiesCurrent borrowings87,500100,000
Current liabilitiesAccounts payable143,292130,201
Current liabilitiesAccrued expenses134,170117,350
Current liabilitiesPayroll and benefit-related liabilities110,214124,769
Current liabilitiesAccrued interest3,5585,404
Current liabilitiesIncome taxes payable17,78718,787
Current liabilitiesOther current liabilities88,364137,195
Current liabilitiesCurrent liabilities of discontinued operations135,494128,320
Current liabilitiesTotal current liabilities720,379762,026
Current liabilitiesLong-term borrowings2,720,5092,541,449
Current liabilitiesDeferred tax liabilities146,141183,749
Current liabilitiesNoncurrent liability for uncertain tax positions3,8023,536
Current liabilitiesNoncurrent operating lease liabilities64,54084,210
Current liabilitiesOther liabilities174,899194,532
Current liabilitiesNon-current liabilities of discontinued operations51,97452,969
Current liabilitiesTotal liabilities3,882,2443,822,471
Commitments and contingenciesTotal shareholders' equity2,904,5343,124,768
Commitments and contingenciesTotal liabilities and shareholders' equity6,786,7786,947,239

Cash Flow

Six Months Ended — (Unaudited) (in thousands)

Six Months Ended – June 30, 2026Six Months Ended – June 29, 2025
Cash flows from operating activities of continuing operations:Net income91,539217,582
Adjustments to reconcile net income to net cash provided by operating activities:(Income) loss from discontinued operations-54,615-97,074
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation expense35,62024,840
Adjustments to reconcile net income to net cash provided by operating activities:Intangible asset amortization expense67,94350,668
Full release

(1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations during the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the “Strategic Divestitures".

(2) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment, (b) the impact of the Italian payback measure, and (c) the impact of foreign exchange.

INNOVATION PIPELINE UPDATE

EZPLAZ BLA Approval

In late July, Teleflex received BLA approval from the U.S. Food and Drug Administration for EZPLAZ™ Freeze Dried Plasma, the first freeze-dried plasma licensed by the FDA. EZPLAZ expands the emergency medicine portfolio within the Company’s Vascular business and is approved for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled bleeding (hemorrhage) when plasma is required and other plasma products are unavailable, including in combat and prehospital settings.

Freesolve Clinical Program Advances... (truncated) randomized controlled trial of Freesolve conducted outside the United States, positioning the Company for a data readout in late 2027; and initiated the U.S. BIOMAG-III pivotal trial, with first patient procedures completed in June at MedStar Washington Hospital Center.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.